Repligen Corporation (RGEN) Stock Analysis

Repligen Corporation (RGEN) is a publicly traded company in the HEALTHCARE sector. It trades at $121.13, carries a market capitalization of $6.94B, a price-to-earnings ratio of 135.27. This page summarizes the public market data, fundamentals, and frequently asked questions for RGEN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL INSTRUMENTS & SUPPLIES

Exchange: NASDAQ

Key Metrics

Market Sentiment

Repligen Corporation currently has a Bullish sentiment score of 0.18.

About Repligen Corporation

Repligen Corporation, headquartered in Waltham, Massachusetts, is a leading provider of bioprocessing technologies and systems that enhance the development and manufacturing of biologic drugs. The company's innovative solutions, which span from upstream to downstream processes, are utilized by biopharmaceutical companies worldwide, including in North America, Europe, and Asia Pacific. With a focus on high-quality products and ongoing innovation, Repligen is well-positioned to capitalize on th...

GNG Research Analysis

GNG Research scores Repligen Corporation (RGEN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RGEN.

Frequently Asked Questions

Does RGEN pay dividends?

Repligen Corporation (RGEN) does not currently pay a regular dividend.

What is RGEN's P/E ratio?

Repligen Corporation has a price-to-earnings (P/E) ratio of 135.27.

What is RGEN's market cap?

Repligen Corporation (RGEN) has a market capitalization of $6.94B with a current stock price of $121.13.